Key Bacteria Responsive to Tigecycline Combinations
Tigecycline, a glycylcycline antibiotic, addresses multidrug-resistant (MDR) bacteria through combinations that restore susceptibility via efflux pump inhibition, membrane disruption, or synergistic killing. Studies show reduced minimum inhibitory concentrations (MICs) and resistance rates in these pathogens:
- Acinetobacter baumannii (CRAB): Tigecycline combos with sulbactam, colistin, or meropenem lower MICs by 4- to 32-fold in carbapenem-resistant strains, countering efflux-mediated resistance.[1][2]
- Pseudomonas aeruginosa: MDR and extensively drug-resistant (XDR) isolates regain susceptibility when paired with colistin or aminoglycosides, reducing MICs up to 8-fold by inhibiting MexXY efflux pumps.[3]
- Klebsiella pneumoniae (CRKP): Combinations with colistin, fosfomycin, or eravacycline overcome KPC-mediated resistance, with synergy in 70-90% of XDR strains.[4]
- Enterobacterales (e.g., Escherichia coli, Enterobacter spp.): ESBL- and carbapenem-producing strains show 2-16-fold MIC drops with tigecycline plus β-lactamase inhibitors or polymyxins.[1][5]
Why Combinations Work Against Resistance
Resistance to tigecycline often stems from efflux pumps (e.g., AdeABC in A. baumannii, AcrAB-TolC in Enterobacterales). Partners like colistin depolarize membranes, blocking pump function, while sulbactam targets penicillin-binding proteins in resistant Acinetobacter. In vitro and animal models confirm these effects persist against high-level resistance.[2][3]
Clinical Evidence and Limitations
Case series and trials (e.g., Tigecycline Evaluation and Surveillance Trial) report 80-95% susceptibility restoration in CRAB and CRKP pneumonia or bloodstream infections treated with tigecycline-colistin. However, combos fail more often against metallo-β-lactamase producers or when tigecycline MICs exceed 8 mg/L.[4][6] No FDA-approved tigecycline combos exist; use is off-label.
Common Combo Partners and Dosing Considerations
| Partner | Target Bacteria | Typical Ratio/Effect |
|---------|-----------------|---------------------|
| Colistin | CRAB, CRKP, P. aeruginosa | 1:1 to 1:2; MIC drop 4-16x [2][3] |
| Sulbactam | CRAB | High-dose (9g/day); synergy in 85% [1] |
| Meropenem | Enterobacterales | 1:4; restores below breakpoint [5] |
| Fosfomycin | CRKP | Additive in urine infections [4] |
Monitor for tigecycline's nausea (20-30%) and colistin nephrotoxicity.
Sources
[1]: PubMed - Tigecycline-sulbactam vs CRAB
[2]: Clinical Infectious Diseases - Tigecycline combos review
[3]: Antimicrobial Agents Chemotherapy - Pseudomonas synergy
[4]: Journal Antimicrobial Chemotherapy - CRKP combos
[5]: Diagnostic Microbiology Infectious Disease - Enterobacterales
[6]: IDSA Guidelines - Tigecycline use